A61K 31/133
Having hydroxy groups
Official title: having hydroxy groups, e.g. sphingosine
A61K31/133 (Having hydroxy groups) appears on 336 US grants and 675 published applications in this corpus.
Search patents in A61K- Granted patents
- 336
- Published applications
- 675
- Assignees
- 362
- Inventors
- 1,236
- Latest grant
- 11 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1997 | 1 | 0 |
| 1998 | 0 | 0 |
| 1999 | 3 | 0 |
| 2000 | 1 | 0 |
| 2001 | 4 | 1 |
| 2002 | 5 | 1 |
| 2003 | 2 | 13 |
| 2004 | 2 | 18 |
| 2005 | 4 | 9 |
| 2006 | 4 | 9 |
| 2007 | 1 | 12 |
| 2008 | 2 | 21 |
| 2009 | 3 | 17 |
| 2010 | 7 | 11 |
| 2011 | 7 | 26 |
| 2012 | 10 | 17 |
| 2013 | 10 | 25 |
| 2014 | 19 | 39 |
| 2015 | 22 | 44 |
| 2016 | 20 | 43 |
| 2017 | 26 | 40 |
| 2018 | 20 | 37 |
| 2019 | 29 | 47 |
| 2020 | 22 | 48 |
| 2021 | 24 | 47 |
| 2022 | 24 | 39 |
| 2023 | 24 | 41 |
| 2024 | 19 | 30 |
| 2025 | 11 | 22 |
| 2026 | 10 | 18 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Method of treating cystic fibrosis airway disease11 Aug 2026US 12,702,649 B2University of Iowa Research Foundation
- Nutritional compositions and infant formula for promoting de novo myealination21 Jul 2026US 12,685,331 B2Societe des Produits Nestle S. A.
- Porous nanocomposite medical implant device9 Jun 2026US 12,648,904 B2Lynthera Corporation
- Artificially synthesized sphingosine derivative lipoid monomer and use of same for delivering nucleic acid19 May 2026US 12,629,421 B2Beijing Baishihekang Pharmaceutical Technology (Bsjpharma) Co., Ltd
- Methods for treating pulmonary non-tuberculous mycobacterial infections5 May 2026US 12,616,708 B2Insmed Incorporated
- Composition for preventing, ameliorating, or treating tuberculosis comprising extract of philadelphus sp. plant as active ingredient3 Sep 2026US 2026/0256859 A1Chungnam National University Hospital
- Fast absorbing trolamine salicylate formulations and compositions27 Aug 2026US 2026/0248818 A1Thee, Inc.
- Non-tuberculosis mycobacteria infection treatment27 Aug 2026US 2026/0248831 A1AN2 Therapeutics, Inc.
- Use of an amantadine mononitrate compound in manufacture of a medicament for the prevention and treatment of hypertension20 Aug 2026US 2026/0242330 A1Guangzhou Magpie Pharmaceuticals Co., Ltd.
- Artificially synthesized sphingosine derivative lipoid monomer and use of same for delivering nucleic acid6 Aug 2026US 2026/0224704 A1Beijing Baishihekang Pharmaceutical Technology (Bsjpharma) Co., Ltd
Most cited
By later US patents
- System and device for preventing restenosis in body vessels119US 6,682,545 B1The Penn State Research Foundation · 2004
- Treatment of skin wounds using polyenylphosphatidylcholine and alkanolamines99US 6,932,963 B22005
- Agent for treating high-risk impaired glucose tolerance46US 6,200,958 B1Takeda Chemical Industries, Ltd. · 2001
- Method and synergistic composition for treating attention deficit/hyperactivity disorder46US 6,541,043 B2DexGen Pharmaceuticals, Inc. · 2003
- Compositions for delivery of drug combinations40US 10,058,507 B2Celator Pharmaceuticals, Inc. · 2018